High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?

Andrea SantamatoPhysical Medicine and Rehabilitation Section-‘OORR Hospital’, University of Foggia, Foggia, ItalyCorrespondence[email protected]

Maurizio RanieriPhysical Medicine and Rehabilitation Section-‘OORR Hospital’, University of Foggia, Foggia, Italy

Vincenzo SolfrizziGeriatric Medicine-Memory Unit and Rare Disease Centre, University of Bari Aldo Moro, Bari, Italy

Madia LozuponeNeurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy

Michele VecchioDepartment of Medical Sciences, UOC Physical Medicine and Rehabilitation, AOU ‘O.V.E-Policlinico’, Catania, Italy

Antonio DanieleInstitute of Neurology, Catholic University of Sacred Heart, Rome, Italy

Antonio GrecoGerontology-Geriatrics Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy

Davide SeripaGerontology-Geriatrics Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy

Giancarlo LogroscinoNeurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy;Department of Clinical Research in Neurology, University of Bari Aldo Moro, ‘Pia Fondazione Cardinale G. Panico’, Lecce, Italy

Francesco PanzaNeurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy;Gerontology-Geriatrics Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy;Department of Clinical Research in Neurology, University of Bari Aldo Moro, ‘Pia Fondazione Cardinale G. Panico’, Lecce, ItalyCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Declaration of interest

This study was supported by ‘Ministero della Salute’, I.R.C.C.S. Research Program, Ricerca Corrente 2015-2017, Linea n. 2 ‘Malattie complesse e terapie innovative’, by the ‘5 x 1000’ voluntary contribution, and by Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN) 2009 Grant 2009E4RM4Z. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?

Information for

Open access

Opportunities

Help and information

High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature